Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha
| Autor: | Mónica Pico, María Jesús Peñarrubia, Felipe Casado, R Arranz, Maria José Requena, Juan Luis Steegmann, Esperanza Lavilla, José María Fernández-Rañada |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent medicine.medical_treatment Alpha interferon Interferon alpha-2 Gastroenterology chemistry.chemical_compound hemic and lymphatic diseases Internal medicine Leukemia Myelogenous Chronic BCR-ABL Positive medicine Humans Interferon alfa Apolipoproteins B Hypertriglyceridemia Triglyceride Apolipoprotein A-I business.industry Cholesterol HDL Myeloid leukemia Interferon-alpha Hematology Middle Aged medicine.disease Recombinant Proteins Cytokine Endocrinology chemistry Toxicity Complication business medicine.drug |
| Zdroj: | American journal of hematology. 49(3) |
| ISSN: | 0361-8609 |
| Popis: | We analyzed serum triglyceride (TG) levels in 22 chronic myeloid leukemia (CML) patients treated with interferon-α (IFN-α). Hypertriglyceridemia was present in one-half of patients at diagnosis, and IFN-α treatment was associated with a further increase in 90% of the total group of patients. This increase was maximal during the first months of therapy. Four patients (18%) reached levels higher than 1,000 mg/dl. This is the first report describing this secondary effect in CML patients treated with IFN-α. © 1995 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text